Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
OBSERVATIONAL STUDY EVALUATING THE EFFICACY OF TARGETED TREATMENTS FOLLOWING TYROSINE KINASE INHIBITORS IN METASTATIC RENAL CELL CARCINOMA PATIENTS AND EFFECTS ON QUALITY OF LIFE: A NATIONAL, MULTICENTER STUDY
Sponsor: Pfizer
A observational or N/A phase clinical study on Renal Cell Carcinoma, this trial is completed. The trial is conducted by Pfizer and has accumulated 17 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 12 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Aug 2019 — Jan 2021 [monthly]
Completed
-
Nov 2018 — Aug 2019 [monthly]
Completed
-
Aug 2018 — Nov 2018 [monthly]
Completed
-
Jun 2018 — Aug 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Jul 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
May 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .